Mayoral-Silva A, Ascencio-Ibarra HC

Idioma: Español
Referencias bibliográficas: 57
Paginas: 37-46
Archivo PDF: 772.85 Kb.

RESUMEN

La carcinomatosis peritoneal se caracteriza por la presencia de numerosos nódulos de diversos tamaños en la superficie del peritoneo. Es consecuencia de la progresión locorregional de tumores malignos gastrointestinales (colorrectal, apendicular y gástrico); o bien ginecológicos o algunos tumores primarios. Se ha demostrado que con la quimioterapia intraperitoneal con hipertermia intraoperatoria la sobrevivencia de los pacientes que tienen carcinomatosis se prolonga, a diferencia de los que sólo reciben quimioterapia intravenosa. Sin embargo, este procedimiento no es inocuo y pueden presentarse varias complicaciones, tanto quirúrgicas, como por el uso de agentes quimioterapéuticos y alteraciones fisiológicas, por lo que es muy importante conocer en el acto anestésico todo el panorama perioperatorio. El Hospital Regional de Alta Especialidad de Oaxaca es sitio de referencia del sureste para este tratamiento quirúrgico, contando con el apoyo del Dr. Jesús Esquivel y el Dr. Paul Sugar Baker, líderes mundiales de dicho procedimiento.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Al-Shammaa H, Li Y. Current status and future strategies of cytorreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World Journal of Gastroenterology 2008;14:1159-66.

2. Yonemura Y, Bandou E. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. European Journal of Surgical Oncology 2006;32:602-6.

3. Sadeghi B, Arvieux C. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-63.

4. Jacquet P, Sugarbaker P. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treatment Research 1996;82:359-74.

5. Verwaal V, van Ruth S. Long term survival of peritoneal carcinomatosis of colorectal origin. Annals of Surgical Oncology 2005;12:65-71.

6. Verwaal V, van Tinteren H. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. British Journal of Surgery 2004;91:739-46.

7. Economou SG, Mrazek R. The intraperitoneal use of nitrogen mustard at the time of operation for cancer. Annals of the New York Academy of Sciences 1958;68:1097-102.

8. Deraco M, Dario B. Peritonectomy and intraperitoneal hyperthermic perfusion: a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Annals of Surgical Oncology 2004;11:393-8.

9. Sugarbaker P, Mora J. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005; 10:112-22.

10. Chua T, Yan T. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Annals of Surgery 2009;249:900-7.

11. Lees D, Kim Y. Anesthetic management of whole body hyperthermia for the treatment of cancer. Anesthesiology 1980;52:418-28.

12. Dickson J. Hyperthermia in the treatment of cancer. Cancer Chemotherapy Research 1974;58:294-6.

13. Sugarbaker P. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. International Journal of Hyperthermia 2007;23:431-42.

14. Stewart J, Shen P. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Annals of Surgical Oncology 2005;12:765-77.

15. Bynum G, Pandolf K. Induced hyperthermia in sedated humans and the concept of critical thermal maximun. American Journal of Physiology 1978;235:R228-36.

16. Mohamed F, Marchettini P. Termal enhancement of new chemotherapeutic agents at moderate hyperthermia. Annals of Surgical Oncology 2003;10:463-8.

17. Spratt J, Adcock R. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Research 1980;40:256-60.

18. Sudarshan G, Crawford D. Anaesthesia for intraperitoneal hyperthermic perfusion. Anaesthesia 1992;47:483-5.

19. Sugarbaker P. Mechanisms of relapse of colorectal cancer. Implications for intraperitoneal chemotherapy. Diseases of Colon & Rectum 1991;2:36-41.

20. Kavanagh M, Ouellet J-F. Guide de practique clinique sur le traitement de la carcinomatose péritonéale par cytoréduction chirurgicale et chimiothérapie hyperthermique intrapéritonéale periopératoire. Bull Cancer 2006;93:867-74.

21. Glockzin G, Schlitt H. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World Journal of Surgical Oncology 2009;7:5-12.

22. López-Berlanga J, DE-Miguel. Experiencia en la anestesia y cuidados postoperatorios de 11 casos de omentectomía y quimioterapia intraperitoneal caliente. Revista Española de Anestesiología y Reanimación 2004;51:423-8.

23. Smeenk R, Verwaal V. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomixoma peritonei. European Journal of Surgical Oncology 2006;32:186-90.

24. Loungnarath R, Causeret S. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Diseases of Colon & Rectum 2005;48:1372-9.

25. Yan T, Edwards G. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesotelioma. Annals of Surgical Oncology 2007;14:515-25.

26. Van Dyke R, Powis G. Lethal effects of co-administration of halotane and cyclophosphamide. Anesthesiology 1983;59:A248.

27. Elias D, Honore C. Peritoneal pseudomyxoma. Results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy British Journal of Surgery 2008;95:1164-71.

28. Verwaal V, van Tinteren H. Toxicity of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology 2004;85:61-7.

29. De Jonje MJ, Verweij J. Renal toxicities of chemotherapy. Seminars in Oncology 2006;33:68-73.

30. González-Moreno S, Ortega-Pérez G. Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Journal of Surgical Oncology 2009;100:287-92.

31. Elias D, Benizri E. Treatment of synchronus peritoneal carcinomatosis and liver metastases from colorectal cancer. European Journal of Surgical Oncology 2006;32:632-6.

32. Gomes da Silva R, Cabanaas J. Limited survival in the treatment of carcinomatosis of colorectal cancer. Diseases of Colon & Rectum 2005;48:2258-63.

33. Kowalski A, Dougherty T. Hyperthermic intraperitoneal chemotherapy. Advances in Anesthesia 2005;23:95-106.

34. Fujimura T, Yonemura Y. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 1190;65:65-71.

35. Shime N, Lee M. Cardiovascular changes during continuous hyperthermic peritoneal perfusion. Anesthesia & Analgesia 1994;78:938-42.

36. Kanakoudis F, Petrou A. Anaesthesia for intraperitoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, oxygen consumption and delivery. Anaesthesia 1996;51:1033-6.

37. Schmidt C, Creutzenberg M. Perioperative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia 2008;63:389-195.

38. Rankovic V, Masirevic V. Hemodynamic and cardiovascular problems during modified hyperthermic intraperitoneal perioperative chemotherapy. Hepato-Gastroenterology 2007;54:364-6.

39. Henderson M, Pettigrew R. Induction of controlled hyperthermia in treatment of cancer. Lancet 1971;1:1275-7.

40. Barlogie B, Corry P. Total body hyperthermia with and without chemotherapy for advanced human neoplasms. Cancer Research 1979;39:1481-9.

41. Natalino M, Zwillich C. Effects of hyperthermia on hypoxic ventilatory response. Journal of Laboratory & Clinical Medicine 1977;89:564-72.

42. Kim Y, Lake C. Hemodynamic and plasma catecholamine responses to hyperthermic cancer therapy in humans. American Journal of Physiology 1979;237:H570-74.

43. Fippel A, von Sandersleben A. Monitoring of whole body hyperthermia with transesophageal ecocoardiography. International Journal of Hyperthermia 2007;23:457-66.

44. Cronau L, Bourke D. General anesthesia for whole-body hyperthermia. Cancer Research 1984;44:4873S-7S.

45. Deja M, Hildebrandt B. Goal directed therapy of cardiac preload in induced whole body hyperthermia. Chest 2005;128:580-6.

46. Miao N, Pingpank J. Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis. Hemodynamic, metabolic and anesthetic considerations. Annals of Surgical Oncology 2009;16:334-44.

47. Harisiadis L, HAll E. Hyperthermia: Biological studies at cellular level. Radiology 1975;117:447-52.

48. Esquivel J, Angulo F. Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open “coliseum” technique. Annals of Surgical Oncology 2000;7:296-300.

49. Schmidt C, Moritz S. Perioperative management of patients with cytoreductive surgery for peritoneal carcinomatosis. Journal of Surgical Oncology 2009;100:297-301.

50. Santoso JT, Lucci JA, III. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity. Cancer Chemotherapy and Pharmacology 2003;52:13-8.

51. De Jonge MJ, Verweij J. Renal Toxicities of Chemotherapy. Seminars in Oncology 2006;33:68-73.

52. Zielmann S, Grote R. The effects of long therm sedation of intestinal function [Article in German]. Anaesthesist 1995;44:S549-58.

53. Fujimoto S, Kokubun M. Prevention of scald injury on the peritoneo-serosal surface in advanced gastric cancer patients treated with intraperitoneal hyperthermic perfusion. International Journal of Hyperthermia 1991;7:543-50.

54. Fujimoto S, Takahashi M. Metabolic changes in cimetidine treatment for scald injury on peritoneo-serosal surface in far advanced gastric cancer patients treated with intraperitoneal hyperethermic perfusion. Surgery Today 1993;1993:396-401.

55. Connor T, Shults M. Determination of the vaporization of solutions of mutagenic antineoplasic agents. Mutation Research 2000;410:85-92.

56. Stuart O, Stephens A. Safety monitoring of the coliseum technique for heated intraooperative intraperitoneal chemotherapy with mitomycin C. Annals of Surgical Oncology 2002;9:186-91.

57. González-Bayón L, González-Moreno S. Safety considerations for operating room personnel during hyperthermic intraoperative chemotherapy perfusion. European Journal of Surgical Oncology 2006;32:619-24.